Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and tolerability of prophylactic emicizumab in Hemophilia A patients with inhibitors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2021-06-11